Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

E. Biçaku · SciRah

Researcher profile · Semantic Scholar

E. Biçaku

Share profile

E. Biçaku — researcher profile on SciRah

h-index: 19
Works: 41
Citations: 1,571

Most-cited papers

Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study.
P. Münster, D. Marchion, E. Biçaku, Morgen L. Schmitt +10 more
2007Journal of Clinical Oncology224 citations Open access
Semantic Scholar
Valproic acid alters chromatin structure by regulation of chromatin modulation proteins.
D. Marchion, E. Biçaku, A. Daud, D. Sullivan +1 more
2005Cancer Research205 citations Open access
Semantic Scholar
Sequence‐specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid
D. Marchion, E. Biçaku, A. Daud, V. Richon +2 more
2004Journal of Cellular Biochemistry185 citations
Semantic Scholar
Addition of a histone deacetylase inhibitor redirects tamoxifen-treated breast cancer cells into apoptosis, which is opposed by the induction of autophagy
S. Thomas, K. Thurn, E. Biçaku, D. Marchion +1 more
2011Breast Cancer Research and Treatment118 citations Open access
Semantic Scholar
Potentiation of a Topoisomerase I Inhibitor, Karenitecin, by the Histone Deacetylase Inhibitor Valproic Acid in Melanoma: Translational and Phase I/II Clinical Trial
A. Daud, J. Dawson, R. Deconti, E. Biçaku +7 more
2009Clinical Cancer Research93 citations Open access
Semantic Scholar
Selective inhibition of histone deacetylase 2 silences progesterone receptor-mediated signaling.
E. Biçaku, D. Marchion, Morgen L. Schmitt, P. Münster
2008Cancer Research91 citations Open access
Semantic Scholar
BAD phosphorylation determines ovarian cancer chemo-sensitivity and patient survival
D. Marchion, H. Cottrill, Y. Xiong, N. Chen +20 more
2011Clinical Cancer Research88 citations Open access
Semantic Scholar
In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlates
D. Marchion, E. Biçaku, A. Daud, D. Sullivan +1 more
2005Molecular Cancer Therapeutics80 citations
Semantic Scholar
HDAC2 regulates chromatin plasticity and enhances DNA vulnerability
D. Marchion, E. Biçaku, J. Turner, Morgen L. Schmitt +2 more
2009Molecular Cancer Therapeutics64 citations
Semantic Scholar
Synergistic Interaction between Histone Deacetylase and Topoisomerase II Inhibitors Is Mediated through Topoisomerase IIβ
D. Marchion, E. Biçaku, J. Turner, A. Daud +2 more
2005Clinical Cancer Research54 citations
Semantic Scholar
BAD-mediated apoptotic pathway is associated with human cancer development
X. Stickles, D. Marchion, E. Biçaku, E. al Sawah +12 more
2015International Journal of Molecular Medicine50 citations Open access
Semantic Scholar
In vitro analysis of ovarian cancer response to cisplatin, carboplatin, and paclitaxel identifies common pathways that are also associated with overall patient survival
E. Biçaku, Y. Xiong, D. Marchion, H. Chon +11 more
2012British Journal of Cancer41 citations Open access
Semantic Scholar
Clinical and Biological Effects of Valproic Acid as a Histone Deacetylase Inhibitor on Tumor and Surrogate Tissues: Phase I/II Trial of Valproic acid and Epirubicin/FEC
P. Munster, D. Marchion, E. Biçaku, M. Lacevic +6 more
2009Clinical Cancer Research36 citations Open access
Semantic Scholar
Human glioma PKC‐ι and PKC‐βII phosphorylate cyclin‐dependent kinase activating kinase during the cell cycle
M. Acevedo-Duncan, R. Patel, S. Whelan, E. Biçaku
200231 citations Open access
Semantic Scholar
Characterizing the efficacy of fermented wheat germ extract against ovarian cancer and defining the genomic basis of its activity
P. Judson, E. al Sawah, D. Marchion, Y. Xiong +10 more
2012International Journal of Gynecologic Cancer27 citations Open access
Semantic Scholar
A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth
D. Marchion, E. Biçaku, Y. Xiong, N. Zgheib +10 more
2013Oncology Report26 citations Open access
Semantic Scholar
BCL2 antagonist of cell death kinases, phosphatases, and ovarian cancer sensitivity to cisplatin
N. Bansal, D. Marchion, E. Biçaku, Y. Xiong +9 more
2012Journal of Gynecologic Oncology24 citations Open access
Semantic Scholar
Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta.
D. Marchion, E. Biçaku, J. Turner, A. Daud +2 more
2005Clinical Cancer Research24 citations
Semantic Scholar
The BCL2 Antagonist of Cell Death pathway influences endometrial cancer cell sensitivity to cisplatin
H. Chon, D. Marchion, Y. Xiong, N. Chen +9 more
2011Gynecologic Oncology23 citations Open access
Semantic Scholar
Cyclin-dependent kinase activating kinase/Cdk7 co-localizes with PKC-iota in human glioma cells.
E. Biçaku, R. Patel, M. Acevedo-Duncan
2005Tissue & Cell15 citations
Semantic Scholar
Phase II trial of vorinostat, a histone deacetylase inhibitor to restore the hormone sensitivity to the anti-estrogen tamoxifen in patients with advanced breast cancer having failed prior aromatase inhibitor therapy
P. Munster, M. Lacevic, Morgen L. Schmitt, E. Biçaku +4 more
200814 citations
Semantic Scholar
The O-glycan pathway is associated with in vitro sensitivity to gemcitabine and overall survival from ovarian cancer
N. Zgheib, Y. Xiong, D. Marchion, E. Biçaku +11 more
2012International Journal of Oncology13 citations Open access
Semantic Scholar
Phase I trial of the histone deacetylase inhibitor, valproic acid and the topoisomerase II inhibitor, epirubicin: A clinical and translational Study
P. Munster, D. Marchion, E. Biçaku, P. Sullivan +5 more
200512 citations
Semantic Scholar
Phase I trial of a sequence-specific combination of the HDAC inhibitor, vorinostat (SAHA) followed by doxorubicin in advanced solid tumor malignancies
A. Daud, Morgen L. Schmitt, D. Marchion, E. Biçaku +6 more
200711 citations
Semantic Scholar
Human glioma PKC-iota and PKC-betaII phosphorylate cyclin-dependent kinase activating kinase during the cell cycle.
M. Acevedo-Duncan, R. Patel, S. Whelan, E. Biçaku
2002Cell Proliferation11 citations
Semantic Scholar
Phase I/II trial combining the HDAC inhibitor, valproic acid (VPA) and FEC100 (5-fluorouracil, epirubicin and cyclophosphamide) in locally advanced/metastatic breast cancer
P. Munster, D. Marchion, Morgen L. Schmitt, E. Biçaku +4 more
20074 citations
Semantic Scholar
Ultrastructural study of protein kinase C-betaII localization during the cell cycle of human glioma cells.
E. Biçaku, M. Acevedo-Duncan
2001Tissue & Cell3 citations
Semantic Scholar
PLAC1 expression in human cancer cells correlates with carboplatin sensitivity and overall survival from ovarian cancer
N. Zgheib, Y. Xiong, D. Marchion, X. Li +6 more
20121 citations
Semantic Scholar
Cisplatin, carboplatin, and paclitaxel: Unique and common pathways that underlie ovarian cancer response
E. Biçaku, Y. Xiong, D. Marchion, X. Stickles +3 more
20111 citations
Semantic Scholar
The histone deacetylase inhibitor-induced potentiation of tamoxifen involves autophagy.
E. Biçaku, D. Marchion, Morgen L. Schmitt, P. Munster
20071 citations
Semantic Scholar
Valproic acid sensitizes human melanoma cells to karenitecin in vitro and in vivo
J. Gump, D. Marchion, E. Biçaku, J. Turner +4 more
20061 citations
Semantic Scholar
MicroRNA and messenger RNA pathways associated with ovarian cancer cell sensitivity to topotecan, gemcitabine and doxorubicin
X. Stickles, E. Biçaku, D. Marchion, N. Chen +5 more
20110 citations
Semantic Scholar
Predictive Biomarkers and Personalized Medicine BAD Phosphorylation Determines Ovarian Cancer Chemosensitivity and Patient Survival
D. Marchion, H. Cottrill, Y. Xiong, N. Chen +20 more
20110 citations
Semantic Scholar
Category : Predictive Biomarkers and Personalized Medicine BAD phosphorylation determines ovarian cancer chemo-sensitivity and patient survival
D. Marchion, H. Cottrill, Y. Xiong, N. Chen +20 more
20110 citations
Semantic Scholar
Abstract 1645: The phosphorylation status of BAD pathway influence to chemo-sensitivity
H. Chon, D. Marchion, Y. Xiong, N. Chen +4 more
20100 citations
Semantic Scholar
Abstract C1: HDAC inhibitors trigger the autophagic switch from prosurvival to prodeath in tamoxifen‐treated breast cancer cells
S. Thomas, K. Thurn, Ashleigh J. Miller, D. Marchion +2 more
20090 citations
Semantic Scholar
Clinical and Biological Effects of Valproic Acid as a Histone Deacetylase Inhibitor on Tumor and Surrogate Tissues : Phase I / II Trial ofValproic acid and Epirubicin /
PamelaMunster, DouglasMarchion, E. Biçaku, M. Lacevic +6 more
20090 citations
Semantic Scholar
Selective depletion of HDAC2 is sufficient to reduce heterochromatin protein expression and induce chromatin decondensation.
D. Marchion, E. Biçaku, Morgen L. Schmitt, P. Munster
20070 citations
Semantic Scholar
PBMCs as a surrogate marker for tumors: A compilation of Phase I/II trials involving the HDAC inhibitor, valproic acid.
Morgen L. Schmitt, D. Marchion, E. Biçaku, P. Munster
20070 citations
Semantic Scholar
376 POSTER Modulation of estrogen and progesterone receptor signaling by selective HDAC inhibition
E. Biçaku, D. Marchion, Morgen L. Schmitt, P. Munster
20060 citations Open access
Semantic Scholar
556 Histone deacetylase inhibitors induce chromatin decondensation by down-regulation of proteins involved in the maintenance of heterochromatin
D. Marchion, E. Biçaku, A. Daud, D. Sullivan +1 more
20040 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

D. Marchion×36
Invite
D. Marchion — researcher profile on SciRah
P. Munster×19
Invite
P. Munster — researcher profile on SciRah
A. Daud×13
Invite
A. Daud — researcher profile on SciRah
X. Stickles×13
Invite
X. Stickles — researcher profile on SciRah

×13

Invite

R. Wenham — researcher profile on SciRah

J. Lancaster×13

Invite

J. Lancaster — researcher profile on SciRah

Invite

S. Apte — researcher profile on SciRah

Invite

Y. Xiong — researcher profile on SciRah

Morgen L. Schmitt×10

Invite

Morgen L. Schmitt — researcher profile on SciRah

Invite

A. Hakam — researcher profile on SciRah

Invite

P. Judson — researcher profile on SciRah

J. Gonzalez-Bosquet×10

Invite

J. Gonzalez-Bosquet — researcher profile on SciRah